Influx Healthtech Expands Capacity and Launches Premium Products

– Influx Healthtech delivered solid Q4FY26 operational performance, expanded capacity with internally funded capex, and launched premium‑margin product formats, while positioning FY27 as a “scale + innovation” year.

• Revenue: No specific figure disclosed; management noted year‑on‑year growth across nutraceutical, cosmetic and veterinary segments, driven by higher utilization and a better margin mix.
• Profit After Tax / Net Profit: Not reported in the update.
• Operating margins: No exact margins given; the company expects margin upside from new high‑margin formats (liposomal, MMTC) and improved plant utilization.
• Key operational highlights:
  • Commissioned new Quick Snap, Liquid Gel Sachet, 3‑Track Blister, Auto Coater, and Auto Powder Filling machines.
  • Completed FAT for a 1,000 kg/hr Pet Food line; an additional bar production line is booked.
  • Total capex of ≈ ₹5 Cr funded entirely from internal accruals, preserving cash and avoiding dilution.
  • Launched innovative product platforms – liposomal range, MMTC, capsule‑in‑capsule, and pellet technologies – targeting premium, science‑backed nutraceuticals.
  • Created 100 % subsidiary OLAHY Wellness Pvt Ltd. to develop functional beverages and healthy snacks, marking a forward‑integration into B2C.
  • Secured audit clearance for operations in Tanzania, enhancing export readiness.
• Management Guidance (FY27):
  • Focus on commercialising the newly commissioned lines.
  • Aim to capture a higher wallet share from existing clients.
  • Target entry into complex premium categories.
  • Pursue selective B2C expansion through OLAHEY.

No quantitative revenue, profit or margin figures were provided in the Q4FY26 business update.